An Open-Label Phase 2 Study of Ofatumumab (Arzerra) in Combination With Oral GSK2110183 in the Treatment of Relapsed and Refractory Chronic Lymphocytic Leukemia (CLL)
Last updated on July 2021Recruitment
- Recruitment Status
- Completed
- Estimated Enrollment
- 31
Summary
- Conditions
- Chronic Lymphocytic Leukemia (CLL)
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT01532700
- Collaborators
- Novartis
- Investigators
- Principal Investigator: Christine Chen, MD University Health Network, Toronto